These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34024035)

  • 21. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
    Buhl R; Tanase AM; Hosoe M; Cao W; Demin I; Bartels C; Jauernig J; Ziegler D; Patalano F; Hederer B; Kanniess F; Tillmann HC
    Pulm Pharmacol Ther; 2020 Jun; 62():101919. PubMed ID: 32387408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
    Shimada S; Vaidya S; Khindri S; Tashiro N; Cheng Y; Hara H; Majumdar T; Woessner R; Furihata K; Kobayashi K
    Int J Clin Pharmacol Ther; 2015 May; 53(5):398-407. PubMed ID: 25740265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
    Beeh KM; Kirsten AM; Tanase AM; Richard A; Cao W; Hederer B; Beier J; Kornmann O; van Zyl-Smit RN
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3923-3936. PubMed ID: 30584293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma:
    Gon Y; Ishii T; Lawrence D; Nikolaev I; Wang D; Sumi K; Nakamura Y
    J Asthma; 2022 Aug; 59(8):1627-1637. PubMed ID: 34346266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
    Miller D; Vaidya S; Jauernig J; Ethell B; Wagner K; Radhakrishnan R; Tillmann HC
    Respir Res; 2020 Sep; 21(1):248. PubMed ID: 32967685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.
    Vaidya SS; Khindri S; Maahs S; Machineni S; Hara H; Juan A; Kaiser G
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):285-95. PubMed ID: 27310329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
    van Geffen WH; Carpaij OA; Westbroek LF; Seigers D; Niemeijer A; Vonk JM; Kerstjens HAM
    Respir Med; 2020 Sep; 171():106064. PubMed ID: 32917359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma.
    Pelaia C; Crimi C; Crimi N; Ricciardi L; Scichilone N; Valenti G; Bonavita O; Andaloro S; Morini P; Rizzi A; Pelaia G
    Expert Rev Respir Med; 2022 Feb; 16(2):183-195. PubMed ID: 34845963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
    Singh D; Wild JM; Saralaya D; Lawson R; Marshall H; Goldin J; Brown MS; Kostikas K; Belmore K; Fogel R; Patalano F; Drollmann A; Machineni S; Jones I; Yates D; Tillmann HC
    Respir Res; 2022 Feb; 23(1):26. PubMed ID: 35144620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways.
    Rogliani P; Ritondo BL; Facciolo F; Matera MG; Nikolaev I; Calzetta L
    Pharmacol Res; 2021 Oct; 172():105801. PubMed ID: 34363950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
    Kardos P; Hagedorn-Peinz I
    Int J Chron Obstruct Pulmon Dis; 2018; 13():69-77. PubMed ID: 29317812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma.
    de Llano LP; Naval E; Mejía N; Domínguez-Ortega J
    Expert Rev Respir Med; 2022 Jan; 16(1):1-15. PubMed ID: 34783265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
    Chapman K; van Zyl-Smit R; Maspero J; Kerstjens HAM; Gon Y; Hosoe M; Tanase AM; Pethe A; Shu X; D'Andrea P
    BMJ Open Respir Res; 2021 Aug; 8(1):. PubMed ID: 34452934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
    Frampton JE
    Drugs; 2014 Mar; 74(4):465-88. PubMed ID: 24604791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
    COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
    Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
    van Zyl-Smit RN; Chapman KR; Kerstjens HAM; Gessner C; Sagara H; Tanase AM; Hosoe M; Pethe A; Lawrence D; Tillmann HC; D'Andrea P
    J Asthma Allergy; 2023; 16():123-134. PubMed ID: 36714049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.